Classes
Publications
- Subcutaneous Infliximab in Refractory Crohn's Disease Patients: A Possible Biobetter?2023 | First Faculty of Medicine, Third Faculty of Medicine, Second Faculty of Medicine, Central Library of Charles University
- Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy2023 | Faculty of Science, First Faculty of Medicine, Second Faculty of Medicine
- Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD2023 | Faculty of Science, First Faculty of Medicine, Second Faculty of Medicine
- On the question of the interchangeability of monoclonal biosimilar antibodies in the treatment of immune-mediated inflammatory diseases2023 | First Faculty of Medicine, Third Faculty of Medicine
- Patient-reported symptoms are a more reliable predictor of the societal burden compared to established physician-reported activity indices in inflammatory bowel disease: a cross-sectional study2023 | First Faculty of Medicine
- Barriers in inflammatory bowel disease care in Central and Eastern Europe: a region-specific analysis2023 | First Faculty of Medicine
- Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study2023 | First Faculty of Medicine
- Switch from biosimilar infliximab CT-P13 to biosimilar infliximab SB-2 in the long-term maintenance therapy in IBD patients - prospective observational study2023 | First Faculty of Medicine
- Bowel preparation before colonoscopy - comparison of bowel cleansing quality and patient's tolerance of several bowel cleansing devices2023 | First Faculty of Medicine
- Two years of the COVID-19 pandemic in the population of Czech patients with inflammatory bowel disease treated with bio-logical therapy - experience of the tertiary IBD center2023 | First Faculty of Medicine
Loading network view...